Morison Ltd., one of the pioneers of pharmaceutical manufacturing in Sri Lanka since 1959, commenced commercial production at its state-of-the-art WHO and EU GMP compliant production facility in Pitipana, Homagama.
Unveiled in late 2020 as Sri Lanka’s first and largest general oral dosage solid and liquid pharmaceutical manufacturing plant, the plant marked the start of commercial production by manufacturing and recently launching its first batches to market commercial chlorphenamine oral solution and paracetamol 500 mg tablets.
Marking a new era in the pharmaceutical manufacturing industry in Sri Lanka, with a commitment to increasing access to high-quality yet affordable medicines, Morison’s LKR 4 billion investment in its new research and of state-of-the-art pharmaceutical manufacturing, is the highest investment to date in the local pharmaceutical industry.
The facility, the first general oral solid and liquid dosage manufacturing facility in Sri Lanka, built to European Union Good Manufacturing Practice (EU-GMP) specifications and quality management systems, has a manufacturing capacity of more than five Bn tablets and two million liters. of cash in two shifts, which can cover up to 40% of national demand.
Managing Director of Morison Limited, Dinesh Athapaththu, said, “With the launch of commercial production at our new factory, Morison continues its 60-year mission of bringing the highest quality products at affordable prices to Sri Lankans. . We are honored to be able to meet the medical needs of our people with locally made essential medicines in times of crisis for the nation.
“Today, we are releasing our first batches of drugs produced at the new facility, with the National Drug Regulatory Authority (NMRA) seal of approval, marking a new era for local pharmaceutical manufacturing. On this trip, we plan to build a high quality pharmaceutical brand made in Sri Lanka and act on our goal of “Making Premium Healthcare Affordable”.
“We aspire to drive this within a six-pillar framework of being truly Sri Lankan, with global quality, at a local price, introducing new therapies, maintaining ethical standards and maintaining credibility. In this venture, we take responsibility for building a cadre of high caliber professionals to drive the pharmaceutical industry of Sri Lanka forward,” he said.
Morison recently launched the first locally manufactured SGLT-2, next-generation diabetes molecule – Empagliflozin at a cost approximately 50% below prevailing market prices. According to the company, it is also working on a new product pipeline which will include some of the latest therapies primarily in the diabetic, cardiovascular and vitamin segments.
Leveraging Hemas Group’s long-standing relationships, Morison has signed contract manufacturing agreements with a few leading regional pharmaceutical companies, which will be operationalized during the year.
Morison hopes he can bring about a step change in the pharmaceutical industry in Sri Lanka while helping to save some much needed foreign exchange at this stage and possibly start an export business.